US to buy 1.7m courses of untested coronavirus treatment molnupiravir from Merck

Merck & Co Inc said on Wednesday the U.S. government has agreed to buy about 1.7 million courses of the company’s experimental coronavirus disease treatment, molnupiravir, for about US$1.2 billion, if it is authorized in the country, Reuters reports.

Molnupiravir is an experimental antiviral therapy Merck is developing with Ridgeback Biotherapeutics for the treatment of coronavirus patients who are not hospitalized.

The drug is currently being assessed in a late-stage trial for its potential to reduce the risk of hospitalization or death.

Merck said it expects to file for the emergency use authorization of molnupiravir in the second half of 2021 at the earliest, pending favorable results from the trial.

The drug is administered orally in capsule form every 12 hours for 5 days and a treatment course contains 10 doses in total.

Merck expects to have more than 10 million courses of therapy available by the end of this year and said it was in discussions with other countries interested in advance purchase agreements for molnupiravir.

Merck has decided to focus on its drugs for coronavirus disease after two vaccines failed to generate desired immune responses, prompting it to abandon the program in January.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.